This announcement contains inside
information as stipulated under the UK version of the
Market Abuse Regulation No 596/2014 which is part of English law by
virtue of the European (Withdrawal) Act 2018, as amended. On
publication of this announcement via a regulatory information
service, this information is considered to be in the public
domain.
14 February
2025
EDX Medical Group
plc
AQSE: EDX
("EDX Medical" or the "Group"
or "Company")
APPOINTMENT OF DIRECTOR &
DEPUTY CHAIR
CAMBRIDGE, UK: EDX Medical
Group plc, which develops innovative digital diagnostic
products and services supporting personalised treatments for
cancer, cardiovascular and infectious diseases, announces today the
appointment of Martin Walton as a board director and deputy chair
of the Group.
Martin Walton's appointment was approved in a resolution passed by the EDX
Medical board of directors on Wednesday February 12.
Martin Walton has more than 35
years' experience
in finance and investment, including 15 years working with global
life sciences companies. He has completed multiple corporate
transactions from spin-outs, seed- and growth- capital raises to
MBOs, M&A, public market listings and sales to strategic and
private equity buyers.
Jason Holt, chair of EDX Medical, commented:
"We are very pleased to
welcome someone of Martin's experience and expertise as deputy
chair. He will be a great asset to the company. This year is
extremely important in the development of the company as we
continue to implement our business strategy through
commercialisation and expansion of our product portfolio and the
further development of sector partnerships. Martin will play a
leading role in evaluating future strategic growth opportunities
including consideration of progression to other public markets
including the AIM market in London and a Hong Kong
listing."
Professor Sir Chris Evans, OBE, founder of EDX Medical,
said: "Martin and I have worked
together closely for more than 22 years on multiple successful fund
raisings and biotech transactions. Martin's long experience in
various public markets will certainly benefit the company as we
take forward our ambitious plans for the future."
Martin Walton said: "I am
delighted to join the board of EDX Medical - a highly promising
company - and to work again with Chris and the team. I will play an
active role in helping drive forward our strategy to become an
eminent developer and supplier of class-leading digital
diagnostics. There is clear demand and need for earlier detection
of disease and intervention on a global scale as well as providing
the most advanced data driven solutions."
In accordance with Aquis Rule 4.9,
Martin Walton has declared the following information. No other
information is required to be disclosed.
Directorships:
|
Current
|
Commencement date
|
Role
|
|
Bradshaw Consulting Ltd
|
Feb 2014
|
Chairman & CEO
|
|
Interrad Medical LLC
|
Dec 2014
|
Non-executive
|
|
Excalibur Medicines Ltd
|
Mar 2020
|
Executive director
|
|
ReNeuron plc
|
Mar 2024
|
Non-executive
|
|
Past
|
Termination date
|
|
|
MaxRSVentures plc
|
Mar 2024
|
Non-executive
|
|
Liverpool Life Sciences Accelerator
Partnership
|
Sept 2022
|
Non-executive (pro bono)
|
|
Iatros Capital Limited
|
Feb 2021
|
Non-executive
|
|
Igraine Ltd
|
Dec 2021
|
Director
|
|
Administration/Liquidations
|
Date
|
Event
|
|
Reneuron plc
(Administration)
|
Mar 2024
|
Administration
|
|
SG Living
|
2012
|
Dissolved via voluntary
strike-off
|
|
Picturesoft (UK) Ltd
|
Oct 2012
|
Dissolved via voluntary
strike-off
|
The board of directors of EDX
Medical plc accept responsibility for this
announcement.
ENDS
Contacts
|
EDX
Medical Group Plc
|
|
|
Dr Mike Hudson (Chief
Executive Officer)
|
+44 (0)7812 345 301
|
|
|
|
|
Oberon Capital
|
|
|
Nick Lovering (Corporate
Adviser)
Adam Pollock (Corporate
Broking)
Mike Seabrook (Corporate
Broking)
|
+44 (0)20 3179 5300
|
|
|
|
|
IFC
Advisory (Investor Relations)
|
|
|
Tim Metcalfe
|
+44 (0)20 3934 6630
|
|
Graham Herring
|
|
|
|
|
|
Media House International
|
|
|
Ramsay Smith
Gary McQueen
|
+44 (0)7788 414856
ramsay@mediahouse.co.uk
+ 44 (0)7834 694609
gary@mediahouse.co.uk
|
Notes for
Editors:
About EDX Medical Group plc
The EDX Medical
Group plc is listed on the Apex Segment of the AQSE
Growth Market (TIDM: EDX).
EDX Medical was founded by
Professor Sir Christopher Evans, OBE, a medical and life
sciences entrepreneur with more than 30 years of experience,
together with CEO, Dr Mike Hudson.
By translating clinical insights
into pragmatic solutions combining advanced biological and digital
technologies, EDX Medical seeks to cost effectively improve the
detection and characterisation of disease in order to personalise
treatment in a timely fashion. Early disease detection and
biologically-based personal treatment optimisation is considered to
be the most impactful way of reducing deaths and lowering the cost
of healthcare globally.
EDX Medical Group provides doctors,
hospitals and insurers/payers with access to a portfolio of the
best clinical diagnostics products and services. The Company
operates its own facilities in Cambridge and Oxford, UK, and has a
number of significant strategic partnerships including; a product
technology collaboration with Thermo Fisher EMEA Ltd, a logistics
partnership with Fedex and a distribution agreement with Caris Life
Sciences inc, each world leaders in their respective
fields.
www.edxmedical.com
